In:
Cancer Science, Wiley, Vol. 109, No. 2 ( 2018-02), p. 403-411
Abstract:
Podoplanin ( PDPN ) is expressed on many tumors and is involved in tumor metastasis. The objective of the present study was to develop an ELISA for determining soluble PDPN ( sPDPN ) levels as a potential novel tumor marker in plasma of patients with cancers for detection of tumor occurrence and metastasis. Mouse monoclonal antibodies ( mA b) against human PDPN were developed and characterized. Two anti‐ PDPN mA b, SZ ‐163 and SZ ‐168, were used in a sandwich ELISA to detect plasma sPDPN in patients with cancers and in normal individuals. The levels of sPDPN were detected in patients with adenocarcinoma (87 cases, 31.09 ± 5.48 ng/ml), squamous cell carcinoma (86 cases, 6.91 ± 0.59 ng/ml), lung cancer (45 cases, 26.10 ± 7.62 ng/ml), gastric cancer (38 cases, 23.71 ± 6.90 ng/ml) and rectal cancer (27 cases, 32.98 ± 9.88 ng/ml), which were significantly higher than those in normal individuals (99 cases, 1.31 ± 0.13 ng/ml) ( P 〈 .0001). Moreover, the sPDPN levels in patients with metastatic cancers were higher (192 cases, 30.35 ± 3.63 ng/ml) than those in non‐metastatic cancer patients (92 cases, 6.28 ± 0.77 ng/ml) ( P 〈 .0001). The post‐treatment sPDPN levels of cancer patients ( n = 156) (4.47 ± 0.35 ng/ml) were significantly lower compared with those seen pre‐treatment ( n = 128) (43.74 ± 4.97 ng/ml) ( P 〈 .0001). These results showed that an ELISA method was successfully established for quantitation of plasma sPDPN and plasma sPDPN levels correlate significantly with tumor occurrence and metastasis.
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2018.109.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6
Permalink